source
- Researchers develop tumor "avatar" model that predicts immunotherapy response with 93% accuracyResearchers at Elephas Biosciences, in collaboration with academic centers, created an ex vivo tumor "avatar" from patient biopsies to test how tumors respond to immunotherapy. They exposed 124 tu…
- Rapport Therapeutics reports Phase 2 success for RAP-219 in bipolar mania trialRapport Therapeutics announced that its lead candidate RAP-219 met the primary endpoint in a Phase 2 study of adults with acute bipolar mania. The double-blind trial enrolled 253 patients and meas…